Repatha cuts death risk 20% in high-risk primary prevention trial
AI Summary- Amgen reported that Repatha reduced mortality among high-risk adults without prior heart attack or stroke.
- 20% was the reported reduction in death risk in more than 12,000 VESALIUS-CV participants.
- The mortality reduction emerged after approximately 1.5 years and continued through 4.6 years median follow-up.